Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 10/20 | 0.52 |
| ▸ | AKR1C2 | P52895 | 10/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.42 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4217344 | 0.91 | AKR1C3 (0.47) | AKR1C3AKR1C2RAB9AABCB1MAPT | |
| SCHEMBL4213868 | 0.87 | AKR1C3 (0.70) | AKR1C3AKR1C2RAB9A | |
| SCHEMBL4210622 | 0.84 | AKR1C3 (0.48) | AKR1C3AKR1C2RAB9AMAPTKMT2A | |
| SCHEMBL4221441 | 0.84 | SIRT2 (0.46) | AKR1C3AKR1C2MAPTALOX15KMT2A | |
| SCHEMBL4214326 | 0.83 | AKR1C3 (0.40) | AKR1C3AKR1C2ABCB1MTNR1AMTNR1B | |
| SCHEMBL4222764 | 0.83 | AKR1C3 (0.49) | AKR1C3AKR1C2RAB9AMAPTKMT2A | |
| SCHEMBL4215772 | 0.83 | SIRT2 (0.45) | AKR1C3AKR1C2MAPTALOX15KMT2A | |
| SCHEMBL4210580 | 0.82 | SIRT2 (0.43) | AKR1C3AKR1C2MAPTKMT2A | |
| SCHEMBL4227910 | 0.82 | MPO (0.46) | RAB9AABCB1MAPTKMT2A | |
| SCHEMBL4210962 | 0.82 | KDM4E (0.47) | RAB9AMAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8327467-B2 | Anthranilic acid derivative or salt thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2012-12-11 | — | — | US | disclosed |
| EP-1860098-B1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO LTD (JP) | 2012-11-14 | — | — | EP | disclosed |
| US-20090105474-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2009-04-23 | — | — | US | disclosed |
| EP-1860098-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2007-11-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105474-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | MMP13, MMP11, MMP3 | AKR1C3 105/4885AKR1C2 287/4885RAB9A 2262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.